NCT06165809View on ClinicalTrials.gov

A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Advanced Malignant Neoplasm
Interventions
DRUG

TQB3015 tablets

TQB3015 is a protein inhibitor

Trial Locations (1)

150000

Harbin Medical University Cancer Hospital, Harbin

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY